Use of treprostinil to improve kidney functions
The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for improving kidney functions, such as urine output, and treating symptoms associated with kidney malfunction or failure. The invention also relates to kits for the improvement of kidney functions and the treatment of symptoms associated with kidney malfunction or failure, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
1. A method for improving at least one kidney function in a subject with a disease or condition that causes kidney malfunction or failure, comprising administering to a subject in need thereof an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, wherein said derivative is an acid derivative of Treprostinil, a pro-drug of Treprostinil, a sustained release form of Treprostinil, an inhaled. form of Treprostinil, an oral form of Treprostinil, a polymorph of Treprostinil or an isomer of Treprostinil.
2. The method of claim 1 , wherein the kidney function is chosen from urine production, removal of excess body fluid, removal of waste products from the blood, maintenance of normal blood chemistry, hormone production or a combination thereof.
3. The method of claim 1 , wherein the kidney function comprises urine production.
4. The method of claim 1 , wherein the disease or condition that causes kidney malfunction or failure comprises an increase in proliferation of mesangial cells.
5. The method of claim 1 , further comprising a reduction or inhibition of proliferation of mesangial cells in the subject with a disease or condition that causes kidney malfunction or failure.
6. The method of claim 1 , wherein a pharmaceutically acceptable salt of Treprostinil is administered.
7. The method of claim 1 , wherein the subject is a human being.
8. The method of claim 1 , wherein the Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, is administered subcutaneously.
9. The method of claim 1 , wherein the Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, is administered by continuous subcutaneous infusion.
10. The method of claim 1 , wherein the Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, is administered intravenously.
11. The method of claim 1 , wherein the Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, is administered in an orally available form selected from the group consisting of tablets and capsules.
12. The method of claim 1 , wherein the Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, is administered by inhalation.
13. The method of claim 1 , wherein the effective amount is at least 1.0 ng/kg of body weight/min.